Method for the prognosis of survival time of a patient suffering from a solid cancer

US9851357B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITE DE PARIS DESCARTES · FR
• Universite Pierre Et Marie Curie (Paris 6) · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

• Catherine Sautes-Fridman · Paris, FR
• Wolf Herve Fridman · Paris, FR
• Marie-Caroline Dieu-Nosjean · Paris, FR
• Jeremy Goc · Paris, FR

Key dates

• Filing date: Jul 11, 2014
• Grant date: Dec 26, 2017
• Expiry date: Jul 11, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/54
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to an in vitro method for the prognosis of survival of a patient suffering from a solid cancer, comprising the quantification of the cell density of CD8+ cells and DC-LAMP+ dendritic cells present in a tumor tissue sample from said patient, wherein a high density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has a favorable prognosis, a high density of CD8+ cells and a low density of DC-LAMP+ dendritic cells indicates that the patient has a poor prognosis, and a low density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has the worst prognosis.